Key result
Sarcolemmal and mitochondrial KATP channels mediate cardioprotection from ischemic and pharmacologic preconditioning.
Answers are grounded in this paper and cite their sources.
Ischemic or myocardial preconditioning (IPC) is a phenomenon whereby brief periods of ischemia have been shown to protect the myocardium against a more sustained ischemic insult. The result of IPC may be manifest as a marked reduction in infarct size, myocardial stunning, or incidence of cardiac arrhythmias. Whereas many endogenous neurotransmitters, peptides, and hormones have been proposed to play a role in the signal transduction pathways mediating the cardioprotective effect of IPC, nearly universal evidence indicates the involvement of the ATP-sensitive potassium (KATP) channel. Initial evidence suggested that the surface or sarcolemmal KATP (sarcKATP) channel triggered or mediated the cardioprotective effects of IPC; however, more recent findings have suggested a major role for a mitochondrial site or possibly a mitochondrial KATP channel (mitoKATP). This review presents evidence that supports a role for these two channels as a trigger and/or downstream mediator in the phenomenon of IPC or pharmacologically induced PC as well as recent evidence that suggests the involvement of a mitochondrial calcium-activated potassium (mitoKca) channel or the electron transport chain in mediating the beneficial effects of IPC or pharmacologically induced PC.
No takes yet. Share an insight, caveat, or question.
Gross et al. (2003) conducted a review in Myocardial ischemia. ATP-sensitive potassium (KATP) channels was evaluated. Sarcolemmal and mitochondrial ATP-sensitive potassium (KATP) channels act as triggers or downstream mediators in the cardioprotective effects of ischemic or pharmacologically induced preconditioning.
Synapse has enriched 10 related papers. Consider them for comparative context: